997 research outputs found

    Secwepemctsin Children's Reader

    Get PDF
    The Secwepemctsin Children's Reader was written at the SCES Language Department on June 2, 1998 by Mona JulesNot peer reviewedChildren's reade

    Secwepemctsin Children's Reader

    Get PDF
    The Secwepemctsin Children's Reader was written at the SCES Language Department on June 2, 1998 by Mona JulesNot peer reviewedChildren's reade

    Health Policy, Equity, and the Lead Poisoning Crisis: A Conversation with Dr. Mona Hanna-Attisha

    Get PDF
    Dr. Mona Hanna-Attisha delivered the 33rd Annual Herbert Lourie Memorial Lecture on Health Policy on Thursday, September 23, 2021. This year\u27s lecture was titled, Health Policy, Equity, and the Lead Poisoning Crisis: A Conversation with Dr. Mona Hanna-Attisha Mona Hanna-Attisha, MD, MPH, FAAP, is founder and director of the Michigan State University and Hurley Children’s Hospital Pediatric Public Health Initiative, an innovative and model public health program in Flint, Michigan. A pediatrician, scientist, activist, and author, Dr. Hanna-Attisha has testified three times before the United States Congress and was awarded the Freedom of Expression Courage Award by PEN America. She was named one of Time magazine’s 100 Most Influential People in the World and recognized as one of USA Today’s Women of the Century for her role in uncovering the Flint water crisis and leading recovery efforts, and most recently, received the 2020 Fries Prize for Improving Health. A frequent contributor to national media outlets, including the New York Times and Washington Post, Dr. Hanna-Attisha has appeared on CNN, MSNBC, BBC and countless other outlets championing the cause of children in Flint and beyond. She is the founding donor of the Flint Child Health and Development Fund (flintkids.org). A Covid-19 survivor, Dr. Hanna-Attisha has donated her convalescent plasma several times while continuing to advocate for health and racial equity. With concentrations in environmental health and health policy, Dr. Hanna-Attisha received her bachelor’s degree and Master of Public Health degree from the University of Michigan. She completed her medical degree from Michigan State University College of Human Medicine and her residency at Children’s Hospital of Michigan in Detroit, where she was chief resident. She is currently a Charles Stewart Mott Endowed Professor of Public Health and an associate professor of pediatrics and human development at Michigan State University College of Human Medicine. Dr. Hanna-Attisha is the author of the widely acclaimed and bestselling book What the Eyes Don’t See: A Story of Crisis, Resistance, and Hope in an American City. For more information on Dr. Hanna-Attisha, please visit www.prhspeakers.com

    ENTREPRENEURSHIP AND FEMALE ENTREPRENEURSHIP IN MARAMURES COUNTY

    Get PDF
    Initiating and developing a business involves a considerable risk and a sustained effort in order to defeat the inertia against what is new. The person initiating a business, assuming the responsibility and risk of its development and benefiting from theentrepreneurship, female entrepreneurship, profit, businesses

    An unexpected protective role of low affinity allergen-specific IgG via the inhibitory receptor FcγRIIb

    No full text
    Background:Induction of allergen-specific IgG antibodies is a critical parameter for successful specific immunotherapy (SIT). IgG antibodies may inhibit IgE-mediated mast cell activation by direct allergen-neutralization or via the inhibitory receptor FcγRIIb. The affinity of IgE antibodies to the allergen has been shown to be critical for cellular activation.Objective:Here we addressed the question of the affinity thresholds of allergen-specific IgG antibodies for inhibition of mast cell activation by using 2 different monoclonal antibodies against the major cat allergen, Fel d 1, both in vitro and in vivo in mice.Methods:The sequences of the two high-affinity mAbs were back-mutated to germ-line, resulting in low affinity (10-7M) antibodies of the exact same specificity.Results:Using these newly generated recombinant antibodies, we demonstrate that low affinity antibodies are still able to inhibit mast cell activation via FcγRIIb but fail to neutralize the allergen.Conclusion:Antibody affinity dictates the mechanism of mast cell inhibition and IgG antibodies triggering the inhibitory FcγRIIb-pathway may show a broader cross-reactivity pattern than previously thought. This indicates that SIT generates a larger protective umbrella of inhibitory IgG antibodies than previously appreciated

    Inside Mona Hatoum

    No full text
    Examines the work of the Lebanese artist Mona Hatoum, whose work is included in the exhibition Rites of Passage at the Tate Gallery, in London (15 June-3 Sept. 1995). The author notes that Hatoum's work is a combination of sculpture, installation, performance, photography and video, and comments on the participation which viewing her work requires from the spectator. She describes the pieces which are included in the exhibition, focusing particularly on the most recent piece Corps Etranger, which uses video and audio technology to present a representation of the female body photographed internally and externally using microscopic medical probes, and discusses the issues raised by such a representation

    Setsatsinas r Secwepmc to Stsmamelt: Eastern Dialect

    Get PDF
    This is a songbook in the eastern dialect of the Secwepemc peoples. It is organized into Primary/Intermediate Songs, Early Childhood/Beginner Songs, Winter and Christmas Songs with the last section containing poems, prayers, finger plays and games. Secwepemc Childrens' songsNot peer reviewedMusic BookTranslation and desktop publishing by Mona Jule

    Virus-like particle vaccinology, from bench to bedside

    Get PDF
    Virus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed to develop antiviral vaccines followed by their use as display platforms to generate any kind of vaccine. Most recently, VLPs have been employed as nanomachines to deliver pharmaceutically active products to specific sites and into specific cells in the body. Here, we focus on the use of VLPs for the development of vaccines with broad fields of indications ranging from classical vaccines against viruses to therapeutic vaccines against chronic inflammation, pain, allergy and cancer. In this review, we take a walk through time, starting with the latest developments in experimental preclinical VLP-based vaccines and ending with marketed vaccines, which earn billions of dollars every year, paving the way for the next wave of prophylactic and therapeutic vaccines already visible on the horizon

    The 3Ds in virus-like particle based-vaccines: "Design, Delivery and Dynamics".

    Get PDF
    Vaccines need to be rationally designed in order be delivered to the immune system for maximizing induction of dynamic immune responses. Virus-like particles (VLPs) are ideal platforms for such 3D vaccines, as they allow the display of complex and native antigens in a highly repetitive form on their surface and can easily reach lymphoid organs in intact form for optimal activation of B and T cells. Adjusting size and zeta potential may allow investigators to further fine-tune delivery to lymphoid organs. An additional way to alter vaccine transfer to lymph nodes and spleen may be the formulation with micron-sized adjuvants that creates a local depot and results in a slow release of antigen and adjuvant. Ideally, the adjuvant in addition stimulates the innate immune system. The dynamics of the immune response may be further enhanced by inclusion of Toll-like receptor ligands, which many VLPs naturally package. Hence, considering the 3Ds in vaccine development may allow for enhancement of their attributes to tackle complex diseases, not usually amenable to conventional vaccine strategies
    corecore